eCite Digital Repository
Pharmacogenomic biomarkers in docetaxel treatment of prostate cancer: from discovery to implementation
Citation
Varnai, R and Koskinen, LM and Mantyla, LE and Szabo, I and FitzGerald, LM and Sipeky, C, Pharmacogenomic biomarkers in docetaxel treatment of prostate cancer: from discovery to implementation, Genes, 10, (8) Article 599. ISSN 2073-4425 (2019) [Refereed Article]
 | PDF 271Kb |
Copyright Statement
Copyright 2019 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/
DOI: doi:10.3390/genes10080599
Abstract
Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines. Based on this work, we suggest that one of the most promising approaches to improve clinical predictive capacity of pharmacogenomic biomarkers in docetaxel treatment of prostate cancer is the use of compound, multigene pharmacogenomic panels defined by specific clinical outcome measures. In conclusion, we discuss the challenges of integrating prostate cancer pharmacogenomic biomarkers into the clinic and the strategies that can be employed to allow a more comprehensive, evidence-based approach to facilitate their clinical integration. Expanding the integration of pharmacogenetic markers in prostate cancer treatment procedures will enhance precision medicine and ultimately improve patient outcomes.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Keywords: | castration resistant prostate cancer, docetaxel, personalised treatment, pharmacogenomic biomarker |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Oncology and carcinogenesis |
| Research Field: | Cancer genetics |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Clinical health not elsewhere classified |
| UTAS Author: | FitzGerald, LM (Dr Liesel Fitzgerald) |
| ID Code: | 134566 |
| Year Published: | 2019 |
| Web of Science® Times Cited: | 7 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2019-08-20 |
| Last Modified: | 2020-08-12 |
| Downloads: | 24 View Download Statistics |
Repository Staff Only: item control page